Discontinued — last reported Q2 '23
Year-over-year, this metric grew by 73.3%, from $254.76M to $441.40M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 46.6% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.88M | $9.38M | $106.90M | $0.00 | $105.53M | $69.77M | $172.01M | $503.74M | $20.50M | $2.47M | $1.90B | $46.21M | $0.00 | $9.00M | $164.09M | $254.76M | $31.40M | $343.77M | $0.00 | $441.40M |
| QoQ Change | — | -52.8% | >999% | -100.0% | — | -33.9% | +146.6% | +192.9% | -95.9% | -87.9% | >999% | -97.6% | -100.0% | — | >999% | +55.3% | -87.7% | +994.9% | -100.0% | — |
| YoY Change | — | — | — | — | +430.8% | +644.0% | +60.9% | — | -80.6% | -96.5% | >999% | -90.8% | -100.0% | +264.2% | -91.3% | +451.3% | — | >999% | -100.0% | +73.3% |